Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse.
[Infections and fingolimod].
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases.
Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response.
SIRT1 deacetylates RORγt and enhances Th17 cell generation.
iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF.
Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.
Sex-related factors in multiple sclerosis susceptibility and progression.
Increased axonal expression of nectin-1 in multiple sclerosis plaques.
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.
Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients.
Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
No impact of adult attachment and temperament on clinical variability in patients with clinically isolated syndrome and early multiple sclerosis.
An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients
Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.
Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
The value of specialty pharmaceuticals - a systematic review.
Acute Cryptococcal Immune Reconstitution Inflammatory Syndrome in a Patient on Natalizumab.

Pages